HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

Adriano M. Pellicelli, Mario Romano, Tommaso Stroffolini, Ettore Mazzoni, Fabrizio Mecenate, Roberto Monarca, Antonio Picardi, Maria E. Bonaventura, Cristina Mastropietro, Pascal Vignally, Arnaldo Andreoli, Massimo Marignani, Cecilia D'Ambrosio, Lucia Miglioresi, Lorenzo Nosotti, Olga Mitidieri, Umberto V. Gentilucci, Claudio Puoti, Giuseppe Barbaro, Angelo BarlattaniCaterina Furlan, Giorgio Barbarini

Research output: Contribution to journalArticle

Abstract

Background: The impact of viral subtype on the rate of sustained virological response (SVR) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated. The aim of this study is to determine whether the HCV genotype 1 subtypes 1a and 1b respond differently to treatment with PEGylated interferon (PEG-IFN) plus ribavirin.Methods: For 48 weeks, 388 " naïve" genotype 1 patients were treated weekly with PEG-IFN α-2a or PEG-INF α-2b combined with daily ribavirin (1000-1200 mg/day). The numbers of patients in whom HCV-RNA was undetectable were compared after 4 (rapid virological response, RVR), 12 (early virological response, EVR), and 48 (end treatment virological response, ETR) weeks of treatment as well as 24 weeks after the last treatment (sustained virological response, SVR).Results: The rate of SVR was higher in subtype 1a patients than subtype 1b patients (55% vs. 43%; p <0.02). Multiple logistic regression analysis showed that infection with genotype 1a (odds ratio(OR) : 1.8; 95% confidence interval (CI): 1.4 to 4.1), age <50 years (OR:7.0; 95% CI 1.1 to 21.2), alanine aminotransferase level (ALT)10 IU/ml (OR: 3.2; 95% CI: 2.7 to 6.9) and fibrosis score <S3 (OR: 3.8; 95% CI:3.2 to 7.4), were all independent predictors of SVR.Conclusion: Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance.Trial registration: ClinicalTrials.gov Identifier: NCT01342003.

Original languageEnglish
Article number162
JournalBMC Gastroenterology
Volume12
DOIs
Publication statusPublished - Nov 16 2012

Keywords

  • Antiviral therapy
  • Genotype 1a
  • HCV genotype 1 subtypes
  • Pegylated interferon
  • Sustained virological response

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b'. Together they form a unique fingerprint.

  • Cite this

    Pellicelli, A. M., Romano, M., Stroffolini, T., Mazzoni, E., Mecenate, F., Monarca, R., Picardi, A., Bonaventura, M. E., Mastropietro, C., Vignally, P., Andreoli, A., Marignani, M., D'Ambrosio, C., Miglioresi, L., Nosotti, L., Mitidieri, O., Gentilucci, U. V., Puoti, C., Barbaro, G., ... Barbarini, G. (2012). HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterology, 12, [162]. https://doi.org/10.1186/1471-230X-12-162